论文部分内容阅读
目的探讨FOLFOX化疗在结直肠癌肝转移手术治疗中的应用价值。方法对116例结直肠癌肝转移患者新辅助化疗的临床资料进行回顾性总结分析。结果 53例肝转移灶缩小,客观有效率(ORR)45.7%。其中21例(18.1%)获得根治性切除,中位生存时间29.2个月。结论术前新辅助化疗,使结直肠癌肝转移患者因肝转移灶的切除而延长了生存期。
Objective To investigate the value of FOLFOX chemotherapy in the treatment of colorectal cancer liver metastases. Methods The clinical data of 116 patients with liver metastases from colorectal cancer were analyzed retrospectively. Results 53 cases of liver metastases shrink, the objective efficiency (ORR) 45.7%. Among them, 21 cases (18.1%) received radical resection and the median survival time was 29.2 months. Conclusions Neoadjuvant chemotherapy before surgery can prolong survival of patients with liver metastases from colorectal cancer due to resection of liver metastases.